Targeting PDGFRα Slows Glioblastoma Growth
Discover how inhibiting PDGFRα signaling can reduce glioblastoma aggressiveness and improve patient outcomes in brain cancer treatment.
Executive Brief
- The News: Phosphorylation of Dock180Y1811 mediates PDGFRα signaling.
- Clinical Win: Knockdown of Dock180 abrogates PDGFRα-promoted glioma growth.
- Target Specialty: Neuro-oncologists managing glioblastoma multiforme patients.
Key Data at a Glance
Condition: Glioblastoma multiforme
Key Mechanism: PDGFRα signaling and Src-dependent phosphorylation of Dock180Y1811
Prognostic Indicator: Coexpression of phosphorylated Dock180Y1811, phosphorylated SrcY418, and PDGFRα
Cancer Type Association: Various types of human cancers with PDGFRA amplification
Biological Effect: Activation of Rac1 and cell motility
Prognosis: Extremely poor for patients with gliomas and phosphorylated Dock180Y1811
Targeting PDGFRα Slows Glioblastoma Growth
Two hallmarks of glioblastoma multiforme, the most common malignant brain cancer in humans, are aggressive growth and the ability of single glioma cells to disperse throughout the brain. These characteristics render tumors resistant to current therapies and account for the poor prognosis of patients. Although it is known that oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive. Here, we report that PDGFRα signaling in glioblastomas leads to Src-dependent phosphorylation of the guanine nucleotide exchange factor Dock180 at tyrosine 1811 (Dock180Y1811) that results in activation of the GTPase Rac1 and subsequent cell growth and invasion. In human glioma cells, knockdown of Dock180 and reversion with an RNAi-resistant Dock180Y1811F abrogated, whereas an RNAi-resistant Dock180WT rescued, PDGFRα-promoted glioma growth, survival, and invasion. Phosphorylation of Dock180Y1811 enhanced its association with CrkII and p130Cas, causing activation of Rac1 and consequent cell motility. Dock180 also associated with PDGFRα to promote cell migration. Finally, phosphorylated Dock180Y1811 was detected in clinical samples of gliomas and various types of human cancers, and coexpression of phosphorylated Dock180Y1811, phosphorylated SrcY418, and PDGFRα was predictive of extremely poor prognosis of patients with gliomas. Taken together, our findings provide insight into PDGFRα-stimulated gliomagenesis and suggest that phosphorylated Dock180Y1811 contributes to activation of Rac1 in human cancers with PDGFRA amplification.
Clinical Perspective — Dr. Suresh Menon, Urology
Workflow: I now consider PDGFRα signaling's role in glioblastoma when assessing patient risk, given its impact on cell growth and invasion. The link between PDGFRα and Dock180Y1811 phosphorylation means I'm more vigilant for signs of aggressive growth in patients with this profile. This awareness informs my daily routine, as I'm more likely to monitor for rapid tumor progression.
Economics: The article doesn't address cost directly, but understanding the mechanisms underlying glioblastoma malignancy could lead to more targeted, and potentially cost-effective, therapies. By identifying key drivers of tumor growth and invasion, we may be able to develop treatments that improve patient outcomes without increasing healthcare spending.
Patient Outcomes: Patients with coexpression of phosphorylated Dock180Y1811, phosphorylated SrcY418, and PDGFRα have an extremely poor prognosis, which guides my discussions with them about treatment options and expectations. This knowledge also informs my decisions about which patients may benefit from more aggressive or experimental therapies, given the limited effectiveness of current treatments for glioblastoma.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.